GLP-1R reporter cell line for diabetes / obesity research

27th June 2024 Source: Glucagon-Like Peptide 1 Receptor (GLP-1R) reporter cell line

Copied link to clipboard!

AMSBIO has launched a Glucagon-Like Peptide 1 Receptor (GLP-1R) reporter cell line.

GLP-1R is known to play a key role in controlling blood sugar levels by enhancing glucose-stimulated insulin secretion. Therefore, there is considerable interest in harnessing regulation of the GLP-1R mediated signaling pathway as a therapeutic approach to type 2 diabetes which has already resulted in the development of several GLP-1 FDA-approved agonists. In addition, GLP-1R agonists have also been shown to contribute to weight management, decrease the potential for cardiovascular diseases and protect pancreatic beta cells.

This new GLP-1R / CRE Luciferase Reporter HEK293 cell line has been engineered to monitor activation of GLP-1R in cells by measuring luciferase activity, making it useful for cell-based binding assays and screening for human GLP-1R agonists. The functionality of AMSBIO’s new GLP-1R/CRE Luciferase Reporter HEK293 Cell line has been validated in dose-response assays using both peptide and small molecule agonists.

To complement this reporter cell line – AMSBIO has also launched gastric inhibitory polypeptide receptor (GIPR) and glucagon receptor (GCGR) reporter cell lines. Along with GLP-1R, these receptors are critical for regulating blood sugar levels. Dual agonists that bind both GIPR/GCGR and GLP-1R show promising results for the treatment of type 2 diabetes and obesity. Therefore, together these cell lines provide a powerful platform for screening of combination therapies by measuring the activity of co-stimulatory targets in response to agonists.

For further information please visit https://www.amsbio.com/cell-lines/cell-lines-for-diabetes-and-obesity-research/ or contact AMSBIO on +31-72-8080244 / +44-1235-828200 / +1-617-945-5033 / [email protected]. To assist investigations into muscle loss caused by GLP-1R agonists – AMSBIO also offers a range of skeletal muscle research products – see https://www.amsbio.com/skeletal-muscle-differentiation/

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products, and services for R&D in the medical, nutrition, cosmetics, and energy industries. AMSBIO has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion, and proliferation. This expertise in cell culture and the ECM allows AMSBIO to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics. For drug discovery research, AMSBIO offers assays, recombinant proteins, and cell lines. Drawing upon a huge and comprehensive biorepository, AMSBIO is widely recognized as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cells and cell therapy applications. This includes GMP cryopreservation technology, and high-quality solutions for viral delivery.

———————

Worldwide HQ

AMS Biotechnology (AMSBIO)

184 Milton Park
Abingdon

Oxon OX14 4SE

Tel: +44-1235-828200
Fax: +44-1235-820482
Email: [email protected]
Web www.amsbio.com

North American HQ

AMSBIO LLC
1035 Cambridge Street
Cambridge
MA 02141
USA

Tel: +1.617.945.5033
Tel: +1.800.987.0985 (toll free)
Email: [email protected]
Web www.amsbio.com

Media Contact

Dr Bill Bradbury [email protected]